Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Vastra Gotaland Region
Seagen Inc.
KaliVir Immunotherapeutics
IDEAYA Biosciences
iOnctura
Sotio Biotech Inc.
Nuvectis Pharma, Inc.
National Institutes of Health Clinical Center (CC)
Royal Marsden NHS Foundation Trust
Seagen Inc.
Novartis
Kezar Life Sciences, Inc.
Bristol-Myers Squibb
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
Incyte Corporation
Actym Therapeutics, Inc.
Novartis
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
Columbia University
Memorial Sloan Kettering Cancer Center
Turnstone Biologics, Corp.